Given the lack of effect on final tumor weight and since calorie restriction exerts its anticancer effects, in part, through inhibition of the IGF-1 axis and possibly through reduction of serum insulin levels [18,20], we hypothesized that combining calorie restriction with IGF-1R blocking antibody therapy would cause additive inhibition of prostate cancer progression and potentially offset the insulin-resistance-inducing effects of IGF-1R inhibition. This evidence concerns the gene IGF1 and Familial prostate cancer.